Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Cambian agrees to be taken over by CareTech for up to £372mln

Analysts at Liberum believe the value of Cambian is "meaningfully greater" than what CareTech has offered for the firm but they see the benefits of the proposed merger
children
CareTech is looking to expand its childcare business

Cambian Group PLC, a provider of education and behavioural health services for children, has agreed to be taken over by CareTech Holdings PLC (LON:CTH) in a deal that could be valued up to £372mln.

CareTech, which offers social care services, has been in talks with Cambian since July as it seeks to expand its child care business.

It is offering cash-and-stock or all cash for Cambian. The cash and stock deal includes 0.267 new shares and 100p in cash for each Cambian share held, representing a total value of 200p per share or £372mln.

Under the all-cash offer, CareTech will pay 190p for each Cambian share. Cambian’s closing share price on Wednesday was 190.5p, which values the group at £353mln. 

Bid lower than first offer

The latest proposals are below CareTech’s first bid in July, which was 220p per share in cash and stock or 200p per share in full cash.

READ: Cambian jumps after around £405mln takeover proposal from social care services rival CareTech

CareTech said it expects the deal to create pre-tax cost synergies of about £6mln per year by 2021.

“The financial rationale for the Transaction is compelling in its potential to generate value for both CareTech shareholders and Cambian shareholders,” said CareTech chairman Farouq Sheikh.

“At the same time, the larger size of the enlarged group means that more funds will be made available to the CareTech Charitable Foundation to accelerate its important work in giving back to the most disadvantaged communities.”

Shares in Cambian rose 1.8% to 194p in mid-morning trading while CareTech edged up 0.7% to 377p.

Liberum sees benefits of enlarged group but downgrades Cambian 

Liberum downgraded Cambian to a 'hold' rating from 'buy' and cut its target price to 200p from 238p.

“In sum, while we clearly believe the value of Cambian is meaningfully greater (previous target price £2.38) than that agreed today, we expect this deal to be completed (subjected to competition authority approval) and can see the attractions of the new combined entity,” said Liberum.

View full CMBN profile View Profile

Cambian Group Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use